Nurix Therapeutics Inc (NRIX) — Capital Reinvestment Ratio

Latest as of November 2023: 0.10x

Nurix Therapeutics Inc (NRIX) has a Capital Reinvestment Ratio of 0.10x as of November 2023, meaning it reinvests 0% of its operating cash flow ($26.69 Million) in capital expenditures ($2.58 Million). Check Nurix Therapeutics Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.10x
Capex / Operating Cash Flow

Operating Cash Flow

$26.69 Million
USD

Capital Expenditures

$2.58 Million
USD

Data as of

Nov 2023
Most recent filing

Nurix Therapeutics Inc Capital Reinvestment Ratio (2019–2019)

This chart tracks Nurix Therapeutics Inc's Capital Reinvestment Ratio across 1 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Nurix Therapeutics Inc.

Annual Capital Reinvestment Ratio for Nurix Therapeutics Inc (2019–2019)

Year-by-year Capital Reinvestment Ratio for Nurix Therapeutics Inc from 2019 to 2019. See NRIX FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (USD) Capital Expenditures YoY Change
2019 2.75x $601.00K $1.65 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow